Evidence profile
MOTS-C (40 mg Vial)
MOTS-c research connects mitochondrial signaling with metabolism and exercise. Published physiological observations and preclinical findings should be read separately from a registered human intervention trial whose results are not posted.
01
Product identity
Match study material and experimental route before interpreting a result.
Human measurements of naturally occurring MOTS-c differ from testing an administered preparation.
02
What has been studied
Primary preclinical study
Metabolic biology
- Population or model
- Cell and animal models
- Study route or material
- Preclinical methods
Early work studied metabolic effects in cell and animal models.[1]
Primary translational study
Exercise and physical function
- Population or model
- Human exercise observations and experimental mouse studies
- Study route or material
- Endogenous measurements and preclinical intervention
Later research combines human exercise observations with experiments in mice. These are complementary forms of evidence with different implications.[2]
Trial registry
A human trial is registered
- Population or model
- Adults with prediabetes and overweight or obesity; planned enrollment of 120
- Study route or material
- Subcutaneous in the registered placebo-controlled trial
The MOTS-MET registration describes a placebo-controlled phase 2 study of subcutaneous MOTS-c in adults with prediabetes and overweight or obesity. Its planned enrollment is 120. As checked on 9 September 2026, the sponsor-submitted record listed recruiting status and no posted results. This is a research record, not a demonstrated treatment benefit.[3]
03
Evidence limits
A human treatment schedule and the clinical benefits of the linked research product are not established by these sources.
The registered trial has no posted outcomes, and its conduct and applicability to the retail product have not been independently established.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
Exact product identity, strength and current stock-lot linkage.
Manufacturer-supported formulation, container, diluent compatibility and storage information.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[5]
05
Approval context
This profile has not established Canadian authorization of the linked research product.[4]
06
Sources and review scope
- MOTS-c metabolic-homeostasis studyPrimary preclinical study · Indexed identity and abstract · Checked 2026-09-08
- MOTS-c exercise and aging studyPrimary translational study · Indexed identity and abstract · Checked 2026-09-08
- MOTS-MET: MOTS-c insulin-sensitivity trial registrationTrial registry · Fresh official ClinicalTrials.gov API status, intervention and results-posting record · Checked 2026-09-09
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: MOTS-C | 40mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.